Vaccinex to Participate in the LifeSci Partners 10th Annual Healthcare Corporate Access Event
05 janv. 2021 08h00 HE
|
Vaccinex, Inc.
ROCHESTER, N.Y., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating cancer and neurodegenerative...
CORRECTION -- Vaccinex to Present Additional SIGNAL Data at Huntington Study Group 2020 Medical Conference
29 oct. 2020 11h15 HE
|
Vaccinex, Inc.
SIGNAL Phase 2 trial data continue to support cognitive benefit and reduced brain atrophy with pepinemab treatment in Huntington’s disease Data provide strong rationale for continued development in...
Vaccinex to Present Additional SIGNAL Data at Huntington Study Group 2020 Medical Conference
29 oct. 2020 07h55 HE
|
Vaccinex, Inc.
SIGNAL Phase 2 trial data continue to support cognitive benefit and reduced brain atrophy with pepinemab treatment in Huntington’s disease Data provide strong rationale for continued development...
Vaccinex, Inc. to Present at the Virtual Investor KOL Roundtable
26 oct. 2020 07h55 HE
|
Vaccinex, Inc.
ROCHESTER, N.Y., Oct. 26, 2020 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating cancer and neurodegenerative...
Top-Line Results of Phase 2 SIGNAL Study in Huntington’s Disease Support Potential for Cognitive Benefit of Pepinemab
22 sept. 2020 07h30 HE
|
Vaccinex, Inc.
Key cognitive endpoints trending towards but did not reach statistical significance in early manifest population. Overall study does not meet pre-specified co-primary endpoints Results support...
Vaccinex Announces Appointment of Robert Scala as Chief Commercial Officer
27 août 2020 08h00 HE
|
Vaccinex, Inc.
ROCHESTER, N.Y., Aug. 27, 2020 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering novel investigational antibody therapies in Huntington’s disease...
Vaccinex, Inc. to Present at the Virtual Investor Fireside Chat Series
09 juin 2020 08h00 HE
|
Vaccinex, Inc.
Live video moderated discussion with President and CEO, Maurice Zauderer, Ph.D., on Tuesday, June 16, at 10:00 AM ET, immediately followed by an interactive Q&A session ROCHESTER, N.Y., June 09,...
Vaccinex Reports First Quarter 2020 Financial Results and Provides Corporate Update
14 mai 2020 08h45 HE
|
Vaccinex, Inc.
Approaching key topline data in non-small cell lung cancer and Huntington’s disease Advancing plans to expand pepinemab development to include Alzheimer’s disease ROCHESTER, N.Y., May 14, 2020 ...
Vaccinex Announces up to $16.5 Million in Equity Financing Agreements and Provides an Update on COVID-19 Impact on its Clinical Programs
31 mars 2020 07h55 HE
|
Vaccinex, Inc.
ROCHESTER, N.Y., March 31, 2020 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering novel investigational antibody therapies in cancer and...
Vaccinex Announces $3 Million Award from the Alzheimer’s Drug Discovery Foundation
10 déc. 2019 08h02 HE
|
Vaccinex, Inc.
ROCHESTER, N.Y., Dec. 10, 2019 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering novel antibody therapies in neurodegenerative diseases and cancer,...